Abbvie Inc (ABBV)

$225.18 +2.19 (0.98%)
Market Cap 394.11B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 23.61
Forward PE 20.95
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 8,735,100
Avg Vol 5,941,666
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 46%
Beta 0.36
Analysts Strong Sell
Price Target $244.54

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Oldpuck
Oldpuck Dec. 11 at 3:34 PM
$ABBV Every drug stock up big today except ABBV, that upgrade yesterday did a lot of good.
0 · Reply
Garibs
Garibs Dec. 11 at 2:48 PM
$ABBV every morning it's the same routine.. dump it and recovers to HOD.. can we start seeing a study uptrend with this dividend king AND growth??
0 · Reply
RodTownsend
RodTownsend Dec. 11 at 1:02 PM
$ABBV diversified pipeline resilience and defensive pharma rotation feeling like a reliable layer of accumulation
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 12:50 PM
ABBV’s oncology engine is turning into a real growth driver. $ABBV’s expanding oncology lineup — from new solid tumor drugs to rising Venclexta sales — is giving the company steady top-line momentum. That kind of breadth matters in this market. Full breakdown here 👉 https://www.zacks.com/stock/news/2802731/heres-how-abbvies-oncology-drugs-are-aiding-top-line-growth?cid=sm-stocktwits-2-2802731-teaser-24332&ADID=SYND_STOCKTWITS_TWEET_2_2802731_TEASER_24332
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 11:50 AM
$ABBV is bolstering its oncology game — but is it enough? 💉 With a diverse pipeline, including therapies like pivekimab sunirine under FDA review, AbbVie is offsetting Imbruvica's decline by expanding its solid tumor portfolio. However, EPS estimates for 2025 and 2026 have slipped recently, and the stock trades at a slight discount to industry averages, while above its five-year mean. Find out if ABBV’s expansion strategy is a winning play here 👉 https://www.zacks.com/stock/news/2802731/heres-how-abbvies-oncology-drugs-are-aiding-top-line-growth?cid=sm-stocktwits-2-2802731-body-24331&ADID=SYND_STOCKTWITS_TWEET_2_2802731_BODY_24331
0 · Reply
BlitzTrade91
BlitzTrade91 Dec. 10 at 9:43 PM
$ABBV maintaining controlled afternoon structure as buyers continue to support
0 · Reply
SleepyFlick
SleepyFlick Dec. 10 at 9:30 PM
$ABBV showing organized steps upward
0 · Reply
adebenderz
adebenderz Dec. 10 at 8:14 PM
$ABBV defensive pharma cash machine, smooth trend name when the market wants safety + yield
0 · Reply
Few_erish
Few_erish Dec. 10 at 7:18 PM
$ABBV defensive growth pharma, if risk-off persists this can keep a steady trend
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 7:14 PM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: JAN 02 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.63 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on ABBV
AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 14 hours ago

AbbVie: Unique Mix Of Growth And Value

1 Major Factor Behind the Healthcare Sector's Recent Surge

Dec 9, 2025, 10:55 AM EST - 1 day ago

1 Major Factor Behind the Healthcare Sector's Recent Surge

JNJ LLY MRK

3 Top Dividend Stocks to Buy in December

Dec 9, 2025, 4:44 AM EST - 2 days ago

3 Top Dividend Stocks to Buy in December

ARCC ENB

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 8, 2025, 1:30 AM EST - 3 days ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Dec 6, 2025, 8:45 AM EST - 5 days ago

The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Could Buying AbbVie Today Set You Up for Life?

Dec 4, 2025, 9:15 AM EST - 7 days ago

Could Buying AbbVie Today Set You Up for Life?

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 4:53 PM EST - 7 days ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 2, 2025, 8:15 AM EST - 9 days ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

2 Top Dividend Stocks to Buy Now and Hold For a Decade

Dec 2, 2025, 7:44 AM EST - 9 days ago

2 Top Dividend Stocks to Buy Now and Hold For a Decade

PFE

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Dec 1, 2025, 5:55 AM EST - 10 days ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years

Nov 29, 2025, 3:30 PM EST - 11 days ago

3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years

HD XOM

Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 12 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 28, 2025, 7:01 AM EST - 13 days ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

8 Dividend Stocks Every Investor Should Consider

Nov 28, 2025, 5:30 AM EST - 13 days ago

8 Dividend Stocks Every Investor Should Consider

AXP COST JPM NVDA PFE PM SPGI

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 25, 2025, 9:30 AM EST - 16 days ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 17 days ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

5 Dividend Stocks to Hold for the Next 10 Years

Nov 24, 2025, 7:25 AM EST - 17 days ago

5 Dividend Stocks to Hold for the Next 10 Years

ARCC ENB O VZ

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 12:47 PM EST - 22 days ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

It's Best Time In 10 Years To Lock In Income: Our Picks

Nov 18, 2025, 9:00 AM EST - 23 days ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 23 days ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

AbbVie Stock Falls 4% -- What Investors Need to Know

Nov 17, 2025, 7:17 AM EST - 24 days ago

AbbVie Stock Falls 4% -- What Investors Need to Know

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Nov 15, 2025, 7:25 AM EST - 26 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

ENB O

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 4:31 PM EST - 26 days ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 26 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 13, 2025, 8:30 AM EST - 4 weeks ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

JNJ

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 4 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 4 weeks ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 12, 2025, 8:30 AM EST - 4 weeks ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 4 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 4 weeks ago

Three Healthcare Buys That Wall Street Loves

AMGN LLY

5 Top Stocks to Buy in November

Nov 11, 2025, 8:49 AM EST - 4 weeks ago

5 Top Stocks to Buy in November

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.

Nov 9, 2025, 11:05 AM EST - 4 weeks ago

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.

CVS UNH

Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now

Nov 9, 2025, 4:21 AM EST - 4 weeks ago

Got $5,000? These Are 3 of the Cheapest Growth Stocks to Buy Right Now

LMT PYPL

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 4 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Nov 6, 2025, 8:45 AM EST - 5 weeks ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

CL ZTS

2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon

Nov 4, 2025, 5:15 AM EST - 5 weeks ago

2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon

MDT

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 5 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

My Favorite Dividend King to Buy in November

Nov 3, 2025, 7:30 AM EST - 5 weeks ago

My Favorite Dividend King to Buy in November

2 Magnificent Dividend Stocks to Buy and Hold Forever

Nov 2, 2025, 9:15 AM EST - 5 weeks ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

ZTS

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

Nov 1, 2025, 11:15 PM EDT - 5 weeks ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 5 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

Why AbbVie Stock Flopped on Friday

Nov 1, 2025, 6:15 AM EDT - 5 weeks ago

Why AbbVie Stock Flopped on Friday

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 5 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 11:47 AM EDT - 5 weeks ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 5 weeks ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 5 weeks ago

AbbVie Lifts Profit Outlook as Sales Rise

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

Oct 31, 2025, 8:20 AM EDT - 5 weeks ago

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings.

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Oct 31, 2025, 7:54 AM EDT - 5 weeks ago

AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 5 weeks ago

AbbVie Reports Third-Quarter 2025 Financial Results

Oldpuck
Oldpuck Dec. 11 at 3:34 PM
$ABBV Every drug stock up big today except ABBV, that upgrade yesterday did a lot of good.
0 · Reply
Garibs
Garibs Dec. 11 at 2:48 PM
$ABBV every morning it's the same routine.. dump it and recovers to HOD.. can we start seeing a study uptrend with this dividend king AND growth??
0 · Reply
RodTownsend
RodTownsend Dec. 11 at 1:02 PM
$ABBV diversified pipeline resilience and defensive pharma rotation feeling like a reliable layer of accumulation
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 12:50 PM
ABBV’s oncology engine is turning into a real growth driver. $ABBV’s expanding oncology lineup — from new solid tumor drugs to rising Venclexta sales — is giving the company steady top-line momentum. That kind of breadth matters in this market. Full breakdown here 👉 https://www.zacks.com/stock/news/2802731/heres-how-abbvies-oncology-drugs-are-aiding-top-line-growth?cid=sm-stocktwits-2-2802731-teaser-24332&ADID=SYND_STOCKTWITS_TWEET_2_2802731_TEASER_24332
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 11:50 AM
$ABBV is bolstering its oncology game — but is it enough? 💉 With a diverse pipeline, including therapies like pivekimab sunirine under FDA review, AbbVie is offsetting Imbruvica's decline by expanding its solid tumor portfolio. However, EPS estimates for 2025 and 2026 have slipped recently, and the stock trades at a slight discount to industry averages, while above its five-year mean. Find out if ABBV’s expansion strategy is a winning play here 👉 https://www.zacks.com/stock/news/2802731/heres-how-abbvies-oncology-drugs-are-aiding-top-line-growth?cid=sm-stocktwits-2-2802731-body-24331&ADID=SYND_STOCKTWITS_TWEET_2_2802731_BODY_24331
0 · Reply
BlitzTrade91
BlitzTrade91 Dec. 10 at 9:43 PM
$ABBV maintaining controlled afternoon structure as buyers continue to support
0 · Reply
SleepyFlick
SleepyFlick Dec. 10 at 9:30 PM
$ABBV showing organized steps upward
0 · Reply
adebenderz
adebenderz Dec. 10 at 8:14 PM
$ABBV defensive pharma cash machine, smooth trend name when the market wants safety + yield
0 · Reply
Few_erish
Few_erish Dec. 10 at 7:18 PM
$ABBV defensive growth pharma, if risk-off persists this can keep a steady trend
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 7:14 PM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: JAN 02 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.63 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
RodTownsend
RodTownsend Dec. 10 at 7:02 PM
$ABBV diverse pipeline and steady cash flow give AbbVie a low-beta shelter with optional upside from pipeline readouts
1 · Reply
Luckyjs38
Luckyjs38 Dec. 10 at 6:17 PM
$ENVB $ABBV
0 · Reply
Luckyjs38
Luckyjs38 Dec. 10 at 5:58 PM
$ENVB adding more its now trading at a market cap under its cash on hand. Ill hold long waiting to see the news with $ABBV if they secure a settlement? stage 1 human trails in early 2026 to start EB-003 they a vast pipeline of patented intellectual properties and huge non-binding contracts for milestones in 2026 and on. my opinion you do you
0 · Reply
Gebinator
Gebinator Dec. 10 at 4:19 PM
$ABBV take the shot, AbbVie. Two shares of $SLS in exchange for one share of $ABBV Time is of the essence. Lives need saving.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 10 at 3:55 PM
$ABBV $BIIB
0 · Reply
IN0V8
IN0V8 Dec. 10 at 3:50 PM
$ABBV Buy HSBC raises target price to $265 from $225 HSBC raises to buy from hold
0 · Reply
Garibs
Garibs Dec. 10 at 3:33 PM
$ABBV maybe the feds will save this stock.. 5 red days already
0 · Reply
Czreri1
Czreri1 Dec. 10 at 3:30 PM
$ABBV and this is with their dividend being so high…the manipulation is stupid
0 · Reply
69daytrader
69daytrader Dec. 10 at 3:24 PM
$ABBV Was some news or something I missed
0 · Reply
Garibs
Garibs Dec. 10 at 3:13 PM
$ABBV when are they gonna stop manipulating this stock..
0 · Reply
Luckyjs38
Luckyjs38 Dec. 10 at 3:06 PM
$ENVB $ABBV
0 · Reply
Luckyjs38
Luckyjs38 Dec. 10 at 2:54 PM
$ENVB so many delusional bag holding shorts don't understand a settlement offer can be announced any day now from $ABBV do your research. understand the potential market cap for EB-003 if proven safe & effective in human trials 🔮🐦‍🔥 = Billions
0 · Reply